$CLBT

GEE DAVID NICHOLAS sold $29K of CLBT

GEE DAVID NICHOLAS (Chief Marketing Officer) sold 2,243 shares of Cellebrite DI Ltd. (CLBT) at $13.10 on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GEE DAVID NICHOLAS
Published May 26, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
medium confidence
Mentioned
$CLBT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

Because the sale is pre-planned, it is less likely to indicate new negative information; it mainly updates insider activity records.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a sustained repricing without accompanying fundamentals.

03

What to watch

The filing does not disclose reasons for sale; without additional insider buys/sells or performance catalysts, signal quality is low.

Relevance 6/10Timing: Immediate filing today; trade impact, if any, is usually short-lived.

Background

The article is an SEC Form 4 insider transaction notice for Cellebrite DI Ltd., showing an officer sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CLBTNeutralMedium confidence
Context

Cellebrite CMO GEE DAVID NICHOLAS sold 2,243 CLBT shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any move would be more about broader tape/sector than this filing.

Evidence & confidence

The transaction is explicitly under a Rule 10b5-1 plan, which typically reduces signaling value versus discretionary selling.

Market effects

Minimal; insider 10b5-1 sales generally do not reset sector expectations for cybersecurity/forensics vendors.

None indicated; filing is US SEC disclosure only.

None indicated; no deal, trial, or regulatory action mentioned.

Counterpoint

10b5-1 sales can be routine liquidity events and may not reflect negative company outlook.

Key entities

  • Cellebrite DI Ltd.

    Subject of the SEC Form 4 insider transaction disclosure.

  • GEE DAVID NICHOLAS

    Chief Marketing Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.